Matthew Johnson heads the cGMP organization at the Duke Human Vaccine Institute, with the goal of accelerating the delivery of novel therapies to phase I clinical trials through the tight coupling of discovery research with cGMP production. He is accountable for leading the development and manufacturing effort for the cGMP manufacture of therapies including development efforts at the Gates/DHVI Protein Production Facility. Dr. Johnson serves as Principal Investigator of the Vaccine Manufacturing and Toxicology Core for the NIH-sponsored Collaborative Influenza Vaccine Innovation Centers (CIVICs) research program, where his team will develop and manufacture under cGMP candidate influenza vaccines for Phase I clinical trials.
Matthew's areas of responsibility include process development, cGMP production, analytical development/testing, and business/financial leadership. Therapeutic areas include cell culture-based production of recombinant proteins, nanoparticles, and VLPs; and mRNA produced enzymatically and formulated in lipid nanoparticles.
Development and production capabilities are focused on single use technologies in five cGMP suites and span programs developed at Duke and its network of academic, non-profit, government and industry collaborators.